Chonlaphat Sukasem

Clinical Pharmacogenetics Implementation Consortium Guideline for <i>HLA</i> Genotype and Use of Carbamazepine and Oxcarbazepine: 2017 Update

Elizabeth J. Phillips, Chonlaphat Sukasem, Michelle Whirl‐Carrillo et al. · Clinical Pharmacology & Therapeutics · 2018 · 285 citations · Full text

Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for <i>CYP2B6</i> and Efavirenz‐Containing Antiretroviral Therapy

Zeruesenay Desta, Roseann S. Gammal, Li Gong et al. · Clinical Pharmacology & Therapeutics · 2019 · 172 citations · Full text

Translational Medicine, Efavirenz‐containing Antiretroviral Therapy, Human Retrovirus +15

Pharmacokinetics of mitragynine in man

Winai Wananukul, Satariya Trakulsrichai, Korbtham Sathirakul et al. · Drug Design Development and Therapy · 2015 · 131 citations · Full text

Risk and association of <i>HLA</i> with oxcarbazepine-induced cutaneous adverse reactions in Asians

Chun‐Bing Chen, Yi‐Hsin Hsiao, Tony Wu et al. · Neurology · 2016 · 121 citations

Associations between HLA class I and cytochrome P450 2C9 genetic polymorphisms and phenytoin-related severe cutaneous adverse reactions in a Thai population

Wichittra Tassaneeyakul, Napat Prabmeechai, Chonlaphat Sukasem et al. · Pharmacogenetics and Genomics · 2016 · 108 citations